🇺🇸 FDA
Patent

US 8106232

3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists

granted A61KA61K31/197A61K31/485

Quick answer

US patent 8106232 (3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists) held by Theravance, Inc. expires Mon Jan 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance, Inc.
Grant date
Tue Jan 31 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/197, A61K31/485, A61K45/06, A61K47/02